Macular pigment in ophthalmic practice; a survey
Macular pigment (MP) might provide some protection against age-related eye disease, and it is now being measured in ophthalmic practice. The purpose of the survey described here was to determine the distribution of MP in a random population of patients in a typical UK ophthalmic practice.
Macular pigment optical density (MPOD) was measured in 56 patients aged 11 to 87 years, mean 52 ± 19, over a 3-month period. Typically, the test requires setting flicker thresholds for a centrally and peripherally viewed blue/green alternating target. Here we describe the results when an age-based estimate of the peripheral value is used, thus avoiding the peripheral setting. In 32 observers, a comparison was made between this and values obtained with the centre and periphery method. Information on smoking habits, iris colour, diabetic status, and ethnicity were recorded.
The overall average MPOD for the population obtained with the centre-only approach for 56 individuals was 0.400 ± 0.165. The centre-only technique was an accurate predictor of values based on centre and peripheral measures, with 95 % limits of agreement of 0.137 OD units. Pearson’s correlation coefficient showed a high correlation between right and left eyes (r = 0.7 (p < 0.001)). There was a small difference between males and females that did not reach statistical significance (r = −0.22). There was a non-statistically significant age-related decline in MPOD in this particular population (r = −0.17). Dark irides were significantly associated with high MPOD (r = 0.28, p < 0.05). MPOD in Type II diabetic patients was 27 % lower than that in non-diabetics (r = 0.29, p < 0.05).
The technique provides similar values of MP optical density to previous reports. As with other HFP-based methods, in a small percentage of older patients, more than one measurement is required before satisfactory results are obtained.
KeywordsMacular pigment Patient survey Ethnicity Diabetes
We thank Teresa Tee for helping in the preparation of this paper
- 15.Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K, Tsipursky M, Nyland J (2004) Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 75:216–230PubMedCrossRefGoogle Scholar
- 17.Richer SP, Stiles W, Graham-Hoffman K, Levin M, Ruskin D, Wrobel J, Park DW, Thomas C (2011) Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973. Optometry 82:667 e6–680 e6CrossRefGoogle Scholar
- 18.Weigert G, Kaya S, Pemp B, Sacu S, Lasta M, Werkmeister RM, Dragostinoff N, Simader C, Garhofer G, Schmidt-Erfurth U, Schmetterer L (2011) Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 52:8174–8178PubMedCrossRefGoogle Scholar
- 19.Berendschot TTJM, Makridaki M, van der Veen RL, Rob LP, Parry NRA, Carden D, Murray IJ (2011) The clear (combination (of) lutein effects (on) aging retina) study; lutein supplementation improves visual acuity and night vision in early Amd; a two-centre, placebo-controlled study. Invest Ophthalmol Vis Sci 52:E-Abstract 3631Google Scholar
- 20.Murray IJ, Makridaki M, van der Veen RL, Carden D, Parry NR, Berendschot TT (2013) Lutein supplementation over a 1 year period in early AMD might have a mild beneficial effect on visual acuity; the CLEAR study. Invest Ophthalmol Vis Sci 54(3):1781–1788. doi: 10.1167/iovs.12-10715 PubMedCrossRefGoogle Scholar
- 21.Khan JC, Thurlby DA, Shahid H, Clayton DG, Yates JR, Bradley M, Moore AT, Bird AC (2006) Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 90:75–80PubMedCrossRefGoogle Scholar